SCHEMBL6805628

SCHEMBL6805628

COc1ccc(OC)c(C(C(=O)O)n2cncc(NC(=O)c3ccccc3)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 5/20 0.46
TSHR P16473 2/20 0.46
POLB P06746 1/20 0.46
TP53 P04637 2/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 4/20 0.43
MAPK1 P28482 2/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ALDH1A1 P00352 3/20 0.41
PGR P06401 1/20 0.41
LMNA P02545 1/20 0.41
NAMPT P43490 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801198 0.93 SMN1; SMN2 (0.48) MEN1KMT2ASMN1; SMN2TSHRPOLB
SCHEMBL6805410 0.90 MAPT (0.46) MEN1KMT2ASMN1; SMN2TP53NPC1
SCHEMBL6799314 0.85 RAB9A (0.49) MEN1KMT2ASMN1; SMN2POLBTP53
SCHEMBL6804140 0.80 ADRA1A (0.40) MEN1KMT2ATSHRGAAMAPT
SCHEMBL6805321 0.78 IDO1 (0.47) KMT2ASMN1; SMN2POLBTP53NPC1
SCHEMBL6805808 0.76 SMN1; SMN2 (0.47) MEN1KMT2ASMN1; SMN2POLBTP53
SCHEMBL6803731 0.75 IDO1 (0.41) SMN1; SMN2POLBTP53NPC1RAB9A
SCHEMBL6800417 0.75 IDO1 (0.48) KMT2ASMN1; SMN2TSHRPOLBTP53
SCHEMBL6803679 0.74 RAB9A (0.50) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL6800431 0.74 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS MEN1 1512/4885KMT2A 2096/4885SMN1; SMN2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.